All In Biotech

Drug Trial Radar · NCT00352144

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

A Six-Month, Chronic Efficacy and Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia: A Randomized Double-Blind, Placebo-Controlled Study

Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 830 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

830

Actual

Start

Oct 2003

Primary completion

Oct 2004

Study completion Oct 2004

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Jul 14, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects with primary insomnia on subjective sleep measures, compared to placebo.

Conditions

  • Primary Insomnia

Interventions

  • EszopicloneDrug

    Eszopiclone 3 mg

  • PlaceboDrug

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average of Subjective Sleep LatencyTime frame: Days -14, 1, 30, 60, 90, 120, 150, 180

Locations

58 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Irvine, California

  • Site not named

    Oakland, California

  • Site not named

    Redlands, California

  • Site not named

    San Diego, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Longmont, Colorado

  • Site not named

    Pueblo, Colorado

  • Site not named

    Clearwater, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Pinellas Park, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Blairsville, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Elk Grove Village, Illinois

  • Site not named

    Northbrook, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    Olathe, Kansas

  • Site not named

    Prairie Village, Kansas

  • Site not named

    Chevy Chase, Maryland

  • Site not named

    Frederick, Maryland

  • Site not named

    Newton, Massachusetts

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Hamilton, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Cary, North Carolina

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.